• Accelerating Sales Growth: 60.2% increase in H1 FY26 vs FY25
• Portfolio Expansion: Launched Empliq™ human tissue product range
• Expanded Hospital Network Access: NervAlign® Nerve Cuff approved for US DoD and VA healthcare systems

ReNerve Limited (ASX: RNV), an Australian biotechnology company developing innovative products for peripheral nerve injury (PNI) repair, announced its half-year financial results for the six months ended 31 December 2025 (1HFY26). The company has continued to broaden its geographic reach and distribution capability, further expand its product portfolio, and build on its sales momentum throughout the period. ReNerve delivered strong revenue growth in the half-year, with sales increasing 60.2% compared to the prior corresponding period to $163,719, reflecting continued commercial momentum. The company also achieved its first commercial sale of its Empliq™ amniotic tissue products, marking another step in the company's transition from a pure R&D business into commercial activities. In November, the NervAlign® Nerve Cuff was approved for use across the US Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems, establishing an ongoing product supply agreement and granting ReNerve preferred supplier status across both networks. This approval allows the NervAlign® Nerve Cuff to be purchased and stocked across DoD hospitals worldwide and VA hospitals throughout the United States, creating a long-term pathway for consistent product adoption and expanded clinical reach. ReNerve also announced regulatory approvals in Malaysia and Hong Kong for the NervAlign® Nerve Cuff, and continued recruitment in the NervAlign® Nerve Cuff clinical study following statistically significant interim results.

ReNerve delivered strong revenue growth in the half-year, with sales increasing 60.2% compared to the prior corresponding period to $163,719.

ReNerve is advancing a complete suite of nerve repair solutions, including the NervAlign® Nerve Cuff, deep dermal tissue products, amniotic tissue product ranges, NervAlign® Nerve Conduit Range, NervAlign® Nerve Guide Matrix, and NervAlign® Bionic Nerve. The company is positioning itself as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and projected to reach $6.2 billion by 2031.